Answers are grounded in this paper and cite their sources.
Background The role of regional nodal irradiation (RNI) after neoadjuvant chemotherapy (NAC) in patients with clinically node-positive (cN1) breast cancer remains controversial among those achieving nodal pathological complete response (ypN0). This multicenter study evaluated the impact of adjuvant RNI on survival outcomes in a real-world cohort. Methods Patients with invasive breast cancer and clinically positive axillary nodes treated with NAC were identified and categorized according to receipt of adjuvant RNI. Propensity score matching (1:1) was performed to balance baseline characteristics. Primary endpoints were 5-yr axillary recurrence-free survival (ARFS) and 5-yr locoregional recurrence-free survival (LRRFS). Results After propensity score matching, 842 patients (421 per group) were analyzed. RNI was not associated with improved 5-yr ARFS (94.9% vs. 95.8%, p=0.546) or 5-yr LRRFS (95.2% vs. 95.6%, p=0.977) when compared to no RNI. Disease-free (p=0.0003) and distant metastases-free (p=0.0002) survival rates were lower with RNI than without RNI, suggesting that patients undergoing RNI were affected by a worst disease. Multivariable analysis confirmed that RNI was not independently associated with ARFS or LRRFS, whereas residual nodal disease (ypN+) was the strongest predictor of poorer ARFS (HR 3.28, p=0.02) and LRRFS (HR 4.21, p=0.008). Conclusions Adjuvant RNI might not improve axillary or locoregional outcomes after NAC in cN+ breast cancer patients, particularly among those achieving ypN0 status. Post-treatment nodal status is strongly associated to locoregional prognosis, supporting consideration of RNI de-escalation in selected ypN0 patients.
No takes yet. Share an insight, caveat, or question.
Sorrentino et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: